The Medicines and Healthcare products Regulatory Agency (MHRA) has opened a consultation on how its legislation and regulatory processes would have to be modified in the event of the UK not securing a deal with the EU after the UK’s exit, with no Implementation Period.
This week, the House of Lords Science and Technology Committee published a report into the Life Sciences Industrial Strategy, asking: "Who's Driving the Bus?"
This week, the Kings Fund published a new report into the cost of medicines looking at how much the health service spends in total on medicines; both generics and branded medicines.
This morning, The Times published an investigation into the transfers of value received by healthcare professionals (HCPs) and healthcare organisations (HCOs) across Europe from the pharmaceutical industry.
As the MHRA publishes an update to pharmaceutical companies on preparing for Brexit, the ABPI reaffirms the importance of patient and public health in negotiations.
The ABPI have responded today to an announcement by the Department of Health & Social Care who have published a 12 week consultation seeking views from interested parties on the recommendations in the Cost-Effectiveness Methodology for Immunisation Programmes and Procurement (CEMIPP).
On Wednesday 21 February, Health and Social Care Secretary Jeremy Hunt announced that Baroness Julia Cumberlege will lead a review into how the NHS responds to safety concerns raised by patients about medicines or medical devices.